- Asahi Kasei acquires Aicuris for approximately €780 million.
- The transaction is expected to close in Q1 fiscal 2026.
- Pritelivir targets HSV infection in immunocompromised patients.
- AIC468 is in development for BK virus in kidney transplant recipients.
Acquisition Details
Asahi Kasei has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million. The transaction is expected to close in the first quarter of fiscal 2026, subject to customary conditions.
Strategic Expansion
This acquisition expands Asahi Kasei’s specialty pharmaceutical platform into severe infectious diseases, aligning with its existing core transplant and nephrology subsidiaries. The company aims to leverage its commercial infrastructure and R&D capabilities to accelerate the development and commercialization of Aicuris’s pipeline.
Pipeline and Financial Impact
Aicuris adds three compounds to Asahi Kasei’s portfolio, including pritelivir for HSV infection in immunocompromised patients and AIC468 for BK virus in kidney transplant recipients. The acquisition is expected to contribute positively to operating income from fiscal 2028 onward, combining immediate royalty income from Prevymis® with potential commercial upside from pritelivir.
Long-term Growth
The acquisition supports Asahi Kasei’s objective of achieving net sales of ¥300 billion in Pharmaceuticals with an operating margin of 15% or higher by fiscal 2030. It is part of a series of strategic investments and portfolio transformations aimed at optimizing the company’s structure and capital efficiency.
